Do Statins Induce or Protect from Acute Kidney Injury and Chronic Kidney Disease: An Update Review in 2018

Overview

Journal J Transl Int Med

Publisher Sciendo

Specialty General Medicine

Date 2018 Apr 3

PMID 29607300

Citations 21

Authors

An Verdoodt

Patrick M Honore

Rita Jacobs

Elisabeth De Waele

Viola Van Gorp

Jouke De Regt

Herbert D Spapen

Affiliations

Soon will be listed here.

Abstract

Statins essentially are cholesterol-lowering drugs that are extensively prescribed for primary and secondary prevention of cardiovascular disease. Compelling evidence suggests that the beneficial effects of statins may not only be due to its ability to control cholesterol levels but also due to a pleiotropic cholesterol-independent anti-inflammatory, antioxidant, endothelial-protective and plaque-stabilizing activity. Along this line, statins may also exert acute and long-term effects on renal function. We present a narrative literature review that summarizes arguments in favor of or against the preventive and/or therapeutic use of statins in kidney-related diseases or complications. We also highlight the ongoing controversy regarding statin therapy in chronic and end-stage kidney disease.

Citing Articles

Comprehensive Review of Lipid Management in Chronic Kidney Disease and Hemodialysis Patients: Conventional Approaches, and Challenges for Cardiovascular Risk Reduction.

Abidor E, Achkar M, Al Saidi I, Lather T, Jdaidani J, Agarwal A J Clin Med. 2025; 14(2).

PMID: 39860649 PMC: 11765848. DOI: 10.3390/jcm14020643.

The pleiotropic effects of statins: a comprehensive exploration of neurovascular unit modulation and blood-brain barrier protection.

Liu J, Lei S, Zhang D, He Q, Sun Y, Zhu H Mol Med. 2024; 30(1):256.

PMID: 39707228 PMC: 11660731. DOI: 10.1186/s10020-024-01025-0.

Short-term effect of atorvastatin on renal oxidative stress, inflammation, and fibrosis in a rat model of streptozotocin-induced diabetes.

Mayyas F J Diabetes Metab Disord. 2024; 24(1):12.

PMID: 39697866 PMC: 11649593. DOI: 10.1007/s40200-024-01514-3.

Incidence and Predictors of Worsening Renal Function in Edoxaban-Treated Atrial Fibrillation Patients Within ETNA-AF-Europe Registry.

Gwechenberger M, Baron-Esquivias G, de Vries T, Siller-Matula J, Manu M, Souza J JACC Adv. 2024; 3(4):100880.

PMID: 38939675 PMC: 11198551. DOI: 10.1016/j.jacadv.2024.100880.

Effects of statins on the incidence and outcomes of acute kidney injury in critically ill patients: a systematic review and meta-analysis.

Vahedian-Azimi A, Heidari Beni F, Fras Z, Banach M, Mohammadi S, Jamialahmadi T Arch Med Sci. 2023; 19(4):952-964.

PMID: 37560738 PMC: 10408035. DOI: 10.5114/aoms/159992.

References

Marenzi G, Cosentino N, Werba J, Tedesco C, Veglia F, Bartorelli A . A meta-analysis of randomized controlled trials on statins for the prevention of contrast-induced acute kidney injury in patients with and without acute coronary syndromes. Int J Cardiol. 2015; 183:47-53. DOI: 10.1016/j.ijcard.2015.01.046. View

Jabbari M, Rostami Z, Jenabi A, Bahrami A, Mooraki A . Simvastatin ameliorates gentamicin-induced renal injury in rats. Saudi J Kidney Dis Transpl. 2011; 22(6):1181-6. View

Rodrigues C . HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Sao Paulo Med J. 2016; 133(6):541-2. PMC: 10496564. DOI: 10.1590/1516-3180.20151336T2. View

Haynes R, Lewis D, Emberson J, Reith C, Agodoa L, Cass A . Effects of lowering LDL cholesterol on progression of kidney disease. J Am Soc Nephrol. 2014; 25(8):1825-33. PMC: 4116066. DOI: 10.1681/ASN.2013090965. View

Wang J, Gu C, Gao M, Yu W, Yu Y . Preoperative Statin Therapy and Renal Outcomes After Cardiac Surgery: A Meta-analysis and Meta-regression of 59,771 Patients. Can J Cardiol. 2015; 31(8):1051-60. DOI: 10.1016/j.cjca.2015.02.034. View

Kato K, Onodera K, Iwasaki Y, Matsuda M, Kawakami T, Higuchi M . Pravastatin-induced rhabdomyolysis and purpura fulminans in a patient with chronic renal failure. Int J Surg Case Rep. 2015; 8C:84-7. PMC: 4353943. DOI: 10.1016/j.ijscr.2015.01.042. View

Virani S, Nambi V, Polsani V, Lee V, Elayda M, Kohsaka S . Preoperative statin therapy decreases risk of postoperative renal insufficiency. Cardiovasc Ther. 2010; 28(2):80-6. DOI: 10.1111/j.1755-5922.2009.00124.x. View

. KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update. Am J Kidney Dis. 2012; 60(5):850-86. DOI: 10.1053/j.ajkd.2012.07.005. View

Honore P, Jacobs R, Hendrickx I, De Waele E, Van Gorp V, Spapen H . Peri-operative fluid strategy and post-operative acute kidney injury in cardiac surgery patients: any role for pre-operative statin therapy?. Crit Care. 2015; 19:453. PMC: 4752014. DOI: 10.1186/s13054-015-1174-4. View

10.

Athyros V, Katsiki N, Tziomalos K, Karagiannis A . Preventing Cardio-renal Syndrome Rather than Treating It: Could Statins Play A Role?. Open Cardiovasc Med J. 2011; 5:226-30. PMC: 3242401. DOI: 10.2174/1874192401105010226. View

11.

Ozbek E, Cekmen M, Ilbey Y, Simsek A, Polat E, Somay A . Atorvastatin prevents gentamicin-induced renal damage in rats through the inhibition of p38-MAPK and NF-kappaB pathways. Ren Fail. 2009; 31(5):382-92. DOI: 10.1080/08860220902835863. View

12.

Hassan Nemati M, Astaneh B . The effects of preoperative statins on the incidence of postoperative acute kidney injury in patients undergoing cardiac surgeries. Interact Cardiovasc Thorac Surg. 2015; 21(4):493-8. DOI: 10.1093/icvts/ivv194. View

13.

Yagi S, Aihara K, Ikeda Y, Akaike M, Sata M, Matsumoto T . Effects of statins on cardiorenal syndrome. Int J Vasc Med. 2012; 2012:162545. PMC: 3390040. DOI: 10.1155/2012/162545. View

14.

Teshima C, Watanabe M, Nakamura S, Vattimo M . Renoprotective effect of statin: a ischemia-reperfusion animal model. Rev Bras Ter Intensiva. 2014; 22(3):245-9. View

15.

Argalious M, Dalton J, Sreenivasalu T, OHara J, Sessler D . The association of preoperative statin use and acute kidney injury after noncardiac surgery. Anesth Analg. 2013; 117(4):916-923. DOI: 10.1213/ANE.0b013e31828175ab. View

16.

Honore P, Jacobs R, Hendrickx I, De Waele E, Van Gorp V, De Regt J . Statins and the Kidney: Friend or Foe?. Blood Purif. 2016; 43(1-3):91-96. DOI: 10.1159/000453577. View

17.

Vaziri N, Norris K . Reasons for the lack of salutary effects of cholesterol-lowering interventions in end-stage renal disease populations. Blood Purif. 2013; 35(1-3):31-6. PMC: 3595172. DOI: 10.1159/000345176. View

18.

Castilla-Guerra L, Fernandez-Moreno M, Colmenero-Camacho M . Statins in Stroke Prevention: Present and Future. Curr Pharm Des. 2016; 22(30):4638-4644. DOI: 10.2174/1381612822666160510125229. View

19.

Wanner C, Krane V, Marz W, Olschewski M, Mann J, Ruf G . Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005; 353(3):238-48. DOI: 10.1056/NEJMoa043545. View

20.

Su X, Zhang L, Lv J, Wang J, Hou W, Xie X . Effect of Statins on Kidney Disease Outcomes: A Systematic Review and Meta-analysis. Am J Kidney Dis. 2016; 67(6):881-92. DOI: 10.1053/j.ajkd.2016.01.016. View